Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of CIN-107 (Baxdrostat) in Healthy Subjects
NCT05500820Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of baxdrostat in hypertension (HTN) (10 cohorts), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 15 more. Started Dec 2019; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05500820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05500820.